TABLE 1.
Distribution of clinical characteristics between case and control
| Characteristics | Total | Case | Control | P‐value | |
|---|---|---|---|---|---|
| (n = 257) | (n = 42) | (n = 215) | |||
| Age at diagnosis (mean ± SD) | 49.3 ± 9.5 | 49.8 ± 8.8 | 49.2 ± 9.7 | .720 | |
| Height (cm) | 157.2 ± 5.0 | 158.1 ± 5.7 | 157.0 ± 4.9 | .221 | |
| Weight (kg) | 58.2 ± 7.9 | 61.6 ± 9.2 | 57.5 ± 7.5 | .002 | |
| Body mass index (BMI) | <25 | 183 | 23 (54.8) | 160 (74.4) | .010 |
| ≥25 | 74 | 19 (45.2) | 55 (25.6) | ||
| Hypertension | No | 214 | 34 (81.0) | 180 (83.7) | .660 |
| Yes | 43 | 8 (19.0) | 35 (16.3) | ||
| Hyperlipidemia | No | 237 | 35 (83.3) | 202 (94.0) | .028 |
| Yes | 20 | 7 (16.7) | 13 (6.1) | ||
| Diabetes | No | 247 | 41 (97.6) | 206 (95.8) | >.999 |
| Yes | 10 | 1 (2.4) | 9 (4.2) | ||
| Other heart disease | No | 252 | 40 (95.2) | 212 (98.6) | .189 |
| Yes | 5 | 2 (4.8) | 3 (1.4) | ||
| Taxol | No | 85 | 11 (26.2) | 74 (34.4) | .300 |
| Yes | 172 | 31 (73.8) | 141 (65.6) | ||
| ER | Negative | 89 | 16 (38.1) | 73 (34.0) | .606 |
| Positive | 168 | 26 (61.9) | 142 (66.0) | ||
| PR | Negative | 104 | 17 (40.5) | 87 (40.5) | .999 |
| Positive | 153 | 25 (59.5) | 128 (59.5) | ||
| HER2 | Negative | 92 | 7 (16.7) | 85 (39.5) | .005 |
| Positive | 165 | 35 (83.3) | 130 (60.5) | ||
| Radiotherapy | No | 21 | 3 (7.1) | 18 (8.4) | >.999 |
| Yes | 236 | 39 (92.9) | 197 (91.6) | ||
| Endocrine therapy | No | 86 | 15 (35.7) | 71 (33.0) | .735 |
| Yes | 171 | 27 (64.3) | 144 (67.0) | ||
| Trastuzumab use | No | 101 | 10 (23.8) | 91 (42.3) | .025 |
| Yes | 156 | 32 (76.2) | 124 (57.7) | ||
| Death | Survival | 231 | 39 (92.9) | 192 (89.3) | |
| Death from breast cancer | 22 | 3 (7.1) | 19 (8.8) | ||
| Death from other cause | 4 | 0 (0.0) | 4 (1.9) | ||
| Progress of ACT | Persistent ACT | 30 | 30 (71.4) | ||
| Transient ACT | 12 | 12 (28.6) |
Abbreviations: ACT: anthracycline‐induced cardiotoxicity; HER2, human epidermal growth factor receptor 2.